Datapoint: Amylyx Pulls ALS Drug Off the Market
Amylyx Pharmaceuticals will pull its ALS drug Relyvrio from the market after it failed to outperform a placebo in a Phase 3 clinical trial, according to an April 4 report from the Associated Press. The drug’s 2022 FDA approval was based on a small clinical trial that showed it only moderately slowed the disease’s progression, a move that proved to be controversial. While Relyvrio is no longer available to new patients, Amylyx said current patients who want to continue taking the drug will be able to enroll in a program to obtain it at no cost. Prior to Amylyx’s announcement, Relyvrio held covered or better status for 57% of all insured lives under the pharmacy benefit, largely with utilization management restrictions applied.
SOURCE: MMIT Analytics, as of 4/10/24